Radiopharmaceutical · developed by Nektar Therapeutics
⁸⁹Zr-Df-IAB22M2C is a zirconium-89 labeled agent studied in metastatic melanoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04955262 | Phase 1 | Metastatic Melanoma | Withdrawn | NKTR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic Melanoma
Updated Oct 25, 2026. Something wrong or missing? Report it on the NKTR page.
See NKTR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NKTR catalysts and pipeline →